ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Identifieur interne : 001205 ( Pmc/Checkpoint ); précédent : 001204; suivant : 001206ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Auteurs : Jordi Rodon [Espagne] ; Mark Rosenthal [Australie] ; Warren Mason [Canada] ; Pedro Perez Segura [Espagne] ; Joseph T. Beck [États-Unis] ; Holger Hirte [Canada] ; John F. Degroot [États-Unis] ; Lucia Trandafir [France] ; Nathalie Pognan [France] ; Lin Yang [États-Unis] ; Charu Kanwal [États-Unis] ; Patrick Y. Wen [États-Unis]Source :
- Neuro-Oncology [ 1522-8517 ] ; 2015.
Url:
DOI: 10.1093/neuonc/nov205.12
PubMed: NONE
PubMed Central: 4638534
Affiliations:
- Australie, Canada, Espagne, France, États-Unis
- Arizona, Catalogne, Communauté de Madrid, Massachusetts, New Jersey, Texas, Victoria (État), Île-de-France
- Barcelone, Madrid, Melbourne, Paris
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:4638534Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ATNT-12<break></break>PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)</title><author><name sortKey="Rodon, Jordi" sort="Rodon, Jordi" uniqKey="Rodon J" first="Jordi" last="Rodon">Jordi Rodon</name><affiliation wicri:level="3"><nlm:aff id="sa12-af1"><addr-line>Hospital Vall d'Hebron, Barcelona, Spain</addr-line></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Vall d'Hebron, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name><affiliation wicri:level="3"><nlm:aff id="sa12-af2"><addr-line>Royal Melbourne Hospital, Melbourne, Australia</addr-line></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Melbourne Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name><affiliation wicri:level="1"><nlm:aff id="sa12-af3"><addr-line>Princess Margaret Cancer Centre, Toronto, ON, Canada</addr-line></nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Segura, Pedro Perez" sort="Segura, Pedro Perez" uniqKey="Segura P" first="Pedro Perez" last="Segura">Pedro Perez Segura</name><affiliation wicri:level="3"><nlm:aff id="sa12-af4"><addr-line>Hospital Clínico San Carlos, Madrid, Spain</addr-line></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínico San Carlos, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Beck, Joseph T" sort="Beck, Joseph T" uniqKey="Beck J" first="Joseph T." last="Beck">Joseph T. Beck</name><affiliation wicri:level="2"><nlm:aff id="sa12-af5"><addr-line>Highlands Oncology Group, Arizona, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Highlands Oncology Group, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hirte, Holger" sort="Hirte, Holger" uniqKey="Hirte H" first="Holger" last="Hirte">Holger Hirte</name><affiliation wicri:level="1"><nlm:aff id="sa12-af6"><addr-line>The Juravinski Cancer Centre, Ontario, Canada</addr-line></nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>The Juravinski Cancer Centre, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Degroot, John F" sort="Degroot, John F" uniqKey="Degroot J" first="John F." last="Degroot">John F. Degroot</name><affiliation wicri:level="2"><nlm:aff id="sa12-af7"><addr-line>University of Texas/MD Anderson Cancer Center, Houston, TX, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas/MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Trandafir, Lucia" sort="Trandafir, Lucia" uniqKey="Trandafir L" first="Lucia" last="Trandafir">Lucia Trandafir</name><affiliation wicri:level="3"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pognan, Nathalie" sort="Pognan, Nathalie" uniqKey="Pognan N" first="Nathalie" last="Pognan">Nathalie Pognan</name><affiliation wicri:level="3"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yang, Lin" sort="Yang, Lin" uniqKey="Yang L" first="Lin" last="Yang">Lin Yang</name><affiliation wicri:level="2"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kanwal, Charu" sort="Kanwal, Charu" uniqKey="Kanwal C" first="Charu" last="Kanwal">Charu Kanwal</name><affiliation wicri:level="2"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Wen, Patrick Y" sort="Wen, Patrick Y" uniqKey="Wen P" first="Patrick Y." last="Wen">Patrick Y. Wen</name><affiliation wicri:level="2"><nlm:aff id="sa12-af10"><addr-line>Dana-Farber Cancer Institute, Boston, MA, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">4638534</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638534</idno><idno type="RBID">PMC:4638534</idno><idno type="doi">10.1093/neuonc/nov205.12</idno><idno type="pmid">NONE</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000150</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000150</idno><idno type="wicri:Area/Pmc/Curation">000150</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000150</idno><idno type="wicri:Area/Pmc/Checkpoint">001205</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001205</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">ATNT-12<break></break>PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)</title><author><name sortKey="Rodon, Jordi" sort="Rodon, Jordi" uniqKey="Rodon J" first="Jordi" last="Rodon">Jordi Rodon</name><affiliation wicri:level="3"><nlm:aff id="sa12-af1"><addr-line>Hospital Vall d'Hebron, Barcelona, Spain</addr-line></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Vall d'Hebron, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name><affiliation wicri:level="3"><nlm:aff id="sa12-af2"><addr-line>Royal Melbourne Hospital, Melbourne, Australia</addr-line></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Royal Melbourne Hospital, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name><affiliation wicri:level="1"><nlm:aff id="sa12-af3"><addr-line>Princess Margaret Cancer Centre, Toronto, ON, Canada</addr-line></nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Segura, Pedro Perez" sort="Segura, Pedro Perez" uniqKey="Segura P" first="Pedro Perez" last="Segura">Pedro Perez Segura</name><affiliation wicri:level="3"><nlm:aff id="sa12-af4"><addr-line>Hospital Clínico San Carlos, Madrid, Spain</addr-line></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Clínico San Carlos, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Beck, Joseph T" sort="Beck, Joseph T" uniqKey="Beck J" first="Joseph T." last="Beck">Joseph T. Beck</name><affiliation wicri:level="2"><nlm:aff id="sa12-af5"><addr-line>Highlands Oncology Group, Arizona, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Highlands Oncology Group, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hirte, Holger" sort="Hirte, Holger" uniqKey="Hirte H" first="Holger" last="Hirte">Holger Hirte</name><affiliation wicri:level="1"><nlm:aff id="sa12-af6"><addr-line>The Juravinski Cancer Centre, Ontario, Canada</addr-line></nlm:aff><country xml:lang="fr">Canada</country><wicri:regionArea>The Juravinski Cancer Centre, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Degroot, John F" sort="Degroot, John F" uniqKey="Degroot J" first="John F." last="Degroot">John F. Degroot</name><affiliation wicri:level="2"><nlm:aff id="sa12-af7"><addr-line>University of Texas/MD Anderson Cancer Center, Houston, TX, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Texas/MD Anderson Cancer Center, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Trandafir, Lucia" sort="Trandafir, Lucia" uniqKey="Trandafir L" first="Lucia" last="Trandafir">Lucia Trandafir</name><affiliation wicri:level="3"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Pognan, Nathalie" sort="Pognan, Nathalie" uniqKey="Pognan N" first="Nathalie" last="Pognan">Nathalie Pognan</name><affiliation wicri:level="3"><nlm:aff id="sa12-af8"><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma S.A.S, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Yang, Lin" sort="Yang, Lin" uniqKey="Yang L" first="Lin" last="Yang">Lin Yang</name><affiliation wicri:level="2"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Kanwal, Charu" sort="Kanwal, Charu" uniqKey="Kanwal C" first="Charu" last="Kanwal">Charu Kanwal</name><affiliation wicri:level="2"><nlm:aff id="sa12-af9"><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Wen, Patrick Y" sort="Wen, Patrick Y" uniqKey="Wen P" first="Patrick Y." last="Wen">Patrick Y. Wen</name><affiliation wicri:level="2"><nlm:aff id="sa12-af10"><addr-line>Dana-Farber Cancer Institute, Boston, MA, USA</addr-line></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Neuro-Oncology</title><idno type="ISSN">1522-8517</idno><idno type="eISSN">1523-5866</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader></TEI><pmc article-type="abstract"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Neuro Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Neuro-oncology</journal-id><journal-id journal-id-type="publisher-id">neuonc</journal-id><journal-id journal-id-type="hwp">neuonc</journal-id><journal-title-group><journal-title>Neuro-Oncology</journal-title></journal-title-group><issn pub-type="ppub">1522-8517</issn><issn pub-type="epub">1523-5866</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4638534</article-id><article-id pub-id-type="doi">10.1093/neuonc/nov205.12</article-id><article-id pub-id-type="publisher-id">nov205</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology</subject><subj-group subj-group-type="heading"><subject>Adult Tumors - Experimental/Novel Therapeutics - Clinical Trials (Non-Immunological) Phases O, I, Combined I-II</subject></subj-group></subj-group></article-categories><title-group><article-title>ATNT-12<break></break>PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rodon</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="sa12-af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rosenthal</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="sa12-af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mason</surname><given-names>Warren</given-names></name><xref ref-type="aff" rid="sa12-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Segura</surname><given-names>Pedro Perez</given-names></name><xref ref-type="aff" rid="sa12-af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Beck</surname><given-names>Joseph T.</given-names></name><xref ref-type="aff" rid="sa12-af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hirte</surname><given-names>Holger</given-names></name><xref ref-type="aff" rid="sa12-af6">6</xref></contrib><contrib contrib-type="author"><name><surname>DeGroot</surname><given-names>John F.</given-names></name><xref ref-type="aff" rid="sa12-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Trandafir</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="sa12-af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Pognan</surname><given-names>Nathalie</given-names></name><xref ref-type="aff" rid="sa12-af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="sa12-af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Kanwal</surname><given-names>Charu</given-names></name><xref ref-type="aff" rid="sa12-af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Patrick Y.</given-names></name><xref ref-type="aff" rid="sa12-af10">10</xref></contrib><aff id="sa12-af1"><label>1</label><addr-line>Hospital Vall d'Hebron, Barcelona, Spain</addr-line></aff><aff id="sa12-af2"><label>2</label><addr-line>Royal Melbourne Hospital, Melbourne, Australia</addr-line></aff><aff id="sa12-af3"><label>3</label><addr-line>Princess Margaret Cancer Centre, Toronto, ON, Canada</addr-line></aff><aff id="sa12-af4"><label>4</label><addr-line>Hospital Clínico San Carlos, Madrid, Spain</addr-line></aff><aff id="sa12-af5"><label>5</label><addr-line>Highlands Oncology Group, Arizona, USA</addr-line></aff><aff id="sa12-af6"><label>6</label><addr-line>The Juravinski Cancer Centre, Ontario, Canada</addr-line></aff><aff id="sa12-af7"><label>7</label><addr-line>University of Texas/MD Anderson Cancer Center, Houston, TX, USA</addr-line></aff><aff id="sa12-af8"><label>8</label><addr-line>Novartis Pharma S.A.S, Paris, France</addr-line></aff><aff id="sa12-af9"><label>9</label><addr-line>Novartis Pharmaceuticals Corporation, New Jersey, USA</addr-line></aff><aff id="sa12-af10"><label>10</label><addr-line>Dana-Farber Cancer Institute, Boston, MA, USA</addr-line></aff></contrib-group><pub-date pub-type="ppub"><month>11</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>09</day><month>11</month><year>2015</year></pub-date><volume>17</volume><issue>Suppl 5</issue><issue-id pub-id-type="doi">10.1093/neuonc/nov202</issue-id><issue-title>Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology, November 19 - 22, 2015, San Antonio, Texas</issue-title><fpage seq="d">v12</fpage><lpage>v13</lpage><permissions><copyright-statement>Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="nov205.12.pdf"></self-uri><custom-meta-group><custom-meta><meta-name>special-property</meta-name><meta-value>meeting-abstract</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc><affiliations><list><country><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>États-Unis</li></country><region><li>Arizona</li><li>Catalogne</li><li>Communauté de Madrid</li><li>Massachusetts</li><li>New Jersey</li><li>Texas</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Madrid</li><li>Melbourne</li><li>Paris</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Rodon, Jordi" sort="Rodon, Jordi" uniqKey="Rodon J" first="Jordi" last="Rodon">Jordi Rodon</name></region><name sortKey="Segura, Pedro Perez" sort="Segura, Pedro Perez" uniqKey="Segura P" first="Pedro Perez" last="Segura">Pedro Perez Segura</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name></region></country><country name="Canada"><noRegion><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name></noRegion><name sortKey="Hirte, Holger" sort="Hirte, Holger" uniqKey="Hirte H" first="Holger" last="Hirte">Holger Hirte</name></country><country name="États-Unis"><region name="Arizona"><name sortKey="Beck, Joseph T" sort="Beck, Joseph T" uniqKey="Beck J" first="Joseph T." last="Beck">Joseph T. Beck</name></region><name sortKey="Degroot, John F" sort="Degroot, John F" uniqKey="Degroot J" first="John F." last="Degroot">John F. Degroot</name><name sortKey="Kanwal, Charu" sort="Kanwal, Charu" uniqKey="Kanwal C" first="Charu" last="Kanwal">Charu Kanwal</name><name sortKey="Wen, Patrick Y" sort="Wen, Patrick Y" uniqKey="Wen P" first="Patrick Y." last="Wen">Patrick Y. Wen</name><name sortKey="Yang, Lin" sort="Yang, Lin" uniqKey="Yang L" first="Lin" last="Yang">Lin Yang</name></country><country name="France"><region name="Île-de-France"><name sortKey="Trandafir, Lucia" sort="Trandafir, Lucia" uniqKey="Trandafir L" first="Lucia" last="Trandafir">Lucia Trandafir</name></region><name sortKey="Pognan, Nathalie" sort="Pognan, Nathalie" uniqKey="Pognan N" first="Nathalie" last="Pognan">Nathalie Pognan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001205 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 001205 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:4638534
|texte= ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |